N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture - PubMed (original) (raw)

Comparative Study

. 1974 Nov 10;249(21):6945-50.

• PMID: 4371054

Free article

Comparative Study

N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture

E A Swyryd et al. J Biol Chem. 1974.

Free article

No abstract available

PubMed Disclaimer

Similar articles

• Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
  Yoshida T, Stark GR, Hoogenraad J. Yoshida T, et al. J Biol Chem. 1974 Nov 10;249(21):6951-5. J Biol Chem. 1974. PMID: 4418148 No abstract available.
• Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
  Baillon J, Guichard M, Malaise EP, Hervé G. Baillon J, et al. Cancer Res. 1983 May;43(5):2277-82. Cancer Res. 1983. PMID: 6831451
• Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
  Friedman J, Moore EC, Hall SW, Loo TL. Friedman J, et al. Cancer Treat Rep. 1979 Jan;63(1):85-8. Cancer Treat Rep. 1979. PMID: 421235
• m-AMSA and PALA: two new agents in cancer chemotherapy.
  Rozencweig M, Von Hoff DD, Cysyk RL, Muggia FM. Rozencweig M, et al. Cancer Chemother Pharmacol. 1979;3(3):135-41. doi: 10.1007/BF00262414. Cancer Chemother Pharmacol. 1979. PMID: 393427 Review.
• Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
  Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B. Grem JL, et al. Cancer Res. 1988 Aug 15;48(16):4441-54. Cancer Res. 1988. PMID: 3293772 Review. No abstract available.

Cited by

• Allosteric regulation of CAD modulates de novo pyrimidine synthesis during the cell cycle.
  Shin J, Mir H, Khurram MA, Fujihara KM, Dynlacht BD, Cardozo TJ, Possemato R. Shin J, et al. Nat Metab. 2023 Feb;5(2):277-293. doi: 10.1038/s42255-023-00735-9. Epub 2023 Feb 6. Nat Metab. 2023. PMID: 36747088 Free PMC article.
• A Tailored Strategy to Crosslink the Aspartate Transcarbamoylase Domain of the Multienzymatic Protein CAD.
  Del Caño-Ochoa F, Rubio-Del-Campo A, Ramón-Maiques S. Del Caño-Ochoa F, et al. Molecules. 2023 Jan 9;28(2):660. doi: 10.3390/molecules28020660. Molecules. 2023. PMID: 36677714 Free PMC article.
• TNFα-induced metabolic reprogramming drives an intrinsic anti-viral state.
  Ciesla J, Moreno I Jr, Munger J. Ciesla J, et al. PLoS Pathog. 2022 Jul 14;18(7):e1010722. doi: 10.1371/journal.ppat.1010722. eCollection 2022 Jul. PLoS Pathog. 2022. PMID: 35834576 Free PMC article.
• Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase.
  Wang C, Krüger A, Du X, Wrenger C, Groves MR. Wang C, et al. Front Cell Infect Microbiol. 2022 Mar 4;12:841833. doi: 10.3389/fcimb.2022.841833. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35310840 Free PMC article. Review.
• Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease.
  Del Caño-Ochoa F, Ramón-Maiques S. Del Caño-Ochoa F, et al. Protein Sci. 2021 Oct;30(10):1995-2008. doi: 10.1002/pro.4158. Epub 2021 Jul 22. Protein Sci. 2021. PMID: 34288185 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database